Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FLT3 exon 15 ins |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06578247 | Phase III | Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Quizartinib | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (QuANTUM-WILD) | Recruiting | USA | SWE | ROU | POL | NOR | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 8 |
| NCT06317649 | Phase II | Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Recruiting | USA | 1 |
| NCT06824168 | Phase II | Quizartinib | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Recruiting | USA | BRA | AUS | 2 |
| NCT07228273 | Phase II | Cytarabine + Daunorubicin Cytarabine + Fludarabine + Idarubicin + Venetoclax | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
| NCT06504459 | Phase II | Cladribine + Cytarabine + Venetoclax Azacitidine + Venetoclax | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | Recruiting | USA | 0 |
| NCT04385290 | Phase Ib/II | Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) | Recruiting | DEU | 0 |
| NCT07059975 | Phase I | Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Idarubicin + Venetoclax Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide Cytarabine + Hydrocortisone + Methotrexate | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | Recruiting | USA | 0 |